about
Pathophysiology of Motor Dysfunction in Parkinson's Disease as the Rationale for Drug Treatment and RehabilitationCommon factors among Alzheimer's disease, Parkinson's disease, and epilepsy: possible role of the noradrenergic nervous systemGait improvement via rhythmic stimulation in Parkinson's disease is linked to rhythmic skillsImaging: What can it tell us about parkinsonian gait?The current status of gene therapy for Parkinson's diseaseDifferential response of the central noradrenergic nervous system to the loss of locus coeruleus neurons in Parkinson's disease and Alzheimer's diseaseProtective effects of SKF-96365, a non-specific inhibitor of SOCE, against MPP+-induced cytotoxicity in PC12 cells: potential role of Homer1.Recurrent Falls in People with Parkinson's Disease without Cognitive Impairment: Focusing on Modifiable Risk FactorsBehavioral impairments and serotonin reductions in rats after chronic L-dopa.Clinical approach to Parkinson's disease: features, diagnosis, and principles of management.Cholinergic dysfunction contributes to gait disturbance in early Parkinson's diseaseGait variability in Parkinson's disease: levodopa and walking direction.Emotional state affects gait initiation in individuals with Parkinson's disease.Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson's Disease Fluctuating Patients: Post hoc Analyses of Studies 016 and SETTLEThe effect of the rehabilitation program on balance, gait, physical performance and trunk rotation in Parkinson's disease.Polymorphism of the COMT, MAO, DAT, NET and 5-HTT Genes, and Biogenic Amines in Parkinson's DiseaseCognitive Stress Reduces the Effect of Levodopa on Parkinson's Resting Tremor.Curved Walking Rehabilitation with a Rotating Treadmill in Patients with Parkinson's Disease: A Proof of Concept.Cholinergic dysfunction in Parkinson's disease.Pharmacological treatment and the prospect of pharmacogenetics in Parkinson's disease.Pains in Parkinson disease--many syndromes under one umbrella.Where attention falls: Increased risk of falls from the converging impact of cortical cholinergic and midbrain dopamine loss on striatal function.Direct and indirect effects of attention and visual function on gait impairment in Parkinson's disease: influence of task and turning.Gait function and locus coeruleus Lewy body pathology in 51 Parkinson's disease patients.The effect of cueing therapy on single and dual-task gait in a drug naïve population of people with Parkinson's disease in northern Tanzania.Neuroanatomic pathways associated with monoaminergic dysregulation after stroke.Shared mechanisms of neurodegeneration in Alzheimer's disease and Parkinson's disease.The Effect of Levodopa on Improvements in Protective Stepping in People With Parkinson's Disease.Response to heat pain stimulation in idiopathic Parkinson's disease.Autonomic symptoms and dopaminergic treatment in de novo Parkinson's disease.Dopaminergic polymorphisms associated with medication responsiveness of gait in Parkinson's disease.Treadmill Training with Cues and Feedback Improves Gait in People with More Advanced Parkinson's Disease.Methylphenidate : a treatment for Parkinson's disease?Dopaminergic medication does not improve stepping responses following backward and forward balance perturbations in patients with Parkinson's disease.Gait freezing and speech disturbance in Parkinson's disease.Instrumental or Physical-Exercise Rehabilitation of Balance Improves Both Balance and Gait in Parkinson's Disease.Model-based and Model-free Machine Learning Techniques for Diagnostic Prediction and Classification of Clinical Outcomes in Parkinson's Disease.Low-fat versus ketogenic diet in Parkinson's disease: A pilot randomized controlled trialAdditive Effects of Levodopa and a Neurorestorative Diet in a Mouse Model of Parkinson's Disease
P2860
Q26745654-802509C5-ABA1-487F-9D67-4D330F4CA342Q27010627-C81B0EFE-0C2E-4E03-AC22-8B4C0E66526AQ30362481-A0BEE360-1479-4829-B480-1F500EB1EECAQ30678856-8140E5F4-9C48-48EE-887C-EE3EAE348C6AQ33979379-42479AC7-9BB3-493A-9A0D-74654A3A64BEQ34572608-22B3CB84-6891-4F86-A676-B9D0B90003C5Q34576781-2BC8E727-58FD-44BE-975F-D5623458087DQ34651698-244BE672-C3A2-4E83-ABE3-373A0F47B855Q35952007-F7154CCA-6769-4B32-B053-F09CFE1B698CQ36009241-B747ADF4-403E-4E3F-85C1-87A9F82D6433Q36218725-FEADB039-DE94-4FC5-A16B-C797E16623F7Q36723256-45B6B406-6C03-4842-9FEE-1879CD8E851BQ36744761-3FD231CD-6511-48B5-A479-459EC647A35EQ37054010-EB890B59-4E98-45ED-B7E2-9B1071A08AFDQ37399303-F7BCFEC0-F401-4792-9E82-B9D7605E53DAQ37583405-66903C99-1075-4498-93C8-197E4B7E3425Q37664152-70CB4ED0-77C6-4597-9A29-3C7F72FBF50FQ37670513-AA9A125B-9DDF-44B1-AA70-920B5D61C565Q37709932-2BA94379-5C49-46E4-92F1-54F2B1AADC6CQ37957393-F7A4C955-00D4-44CC-BD42-B3742734996DQ38003055-0CFD3100-CCFB-46DC-B354-5FCA54A3ADCBQ38209988-6A896ED6-8A87-40C8-8AF2-DF69BAEC98A3Q38690675-6B04F52D-A240-4A9B-8809-1274BCFE3D92Q39332170-CF285331-B885-426D-BC7B-DA4A87B72114Q39403465-93CB3F8E-47CA-4FA8-8702-17E5E61D8E6CQ39717355-7C18336D-A5B2-4AFA-8257-81BF5208C06CQ40017984-2DDC1560-29B1-463B-8A91-A107BB2A15A6Q42646983-936B18DE-B801-477A-932F-1ACBFD0CE55DQ42972671-3F2838B0-9239-489F-8911-114CD3D1A196Q43459747-DD176F0E-57FF-4178-B9A0-3D8380799EA5Q47295021-6D664678-E720-496B-BE59-6F7AF114CD07Q47381109-1A620392-355A-4DF1-A9C3-3D84B1565C29Q48290666-6B0097B4-AF6D-4034-81DB-4973D53F0AC3Q48537617-4D4BB05F-F9A2-4FF5-8331-04509D1FBF2AQ53318350-AD2957D9-D03E-4303-B666-FB7CD8EA334FQ54937647-CE04F7E0-4A32-4397-83AB-1BB90324D70DQ55345239-D2774199-41EE-4789-B261-BE331B2210C0Q58788080-49F9BDFE-9D8F-428D-B60F-BAC1CEAF89A1Q58801455-BE21D340-3FAE-424C-8951-47C1BA08B3FE
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Levodopa unresponsive symptoms in Parkinson disease.
@en
Levodopa unresponsive symptoms in Parkinson disease.
@nl
type
label
Levodopa unresponsive symptoms in Parkinson disease.
@en
Levodopa unresponsive symptoms in Parkinson disease.
@nl
prefLabel
Levodopa unresponsive symptoms in Parkinson disease.
@en
Levodopa unresponsive symptoms in Parkinson disease.
@nl
P2860
P356
P1433
P1476
Levodopa unresponsive symptoms in Parkinson disease.
@en
P2093
Kapil Sethi
P2860
P304
P356
10.1002/MDS.22049
P407
P478
23 Suppl 3
P577
2008-01-01T00:00:00Z